Table 2.
Sequence of first- and second-line regimens.
| First-line regimen (N=503), n (%) | Temozolomidea,b | Temozolomidea + bevacizumab | Temozolomidea + bevacizumab + otherc | Temozolomidea + otherd | Other monotherapy or combinations |
|
| |||||
| 385 (76.5) | 50 (9.9) | 13 (2.6) | 12 (2.4) | 43 (8.5) | |
|
| |||||
| Second-line regimene | |||||
| Bevacizumab | 246 (63.9) | 30 (60.0) | 4 (30.8) | 1 (8.3) | 11 (25.6) |
| Bevacizumab + irinotecan | 70 (18.2) | 4 (8.0) | 3 (23.1) | 3 (25.0) | 2 (4.7) |
| Bevacizumab + temozolomidea | 10 (2.6) | 1 (2.0) | 0 (0) | 1 (8.3) | 0(0) |
| Bevacizumab + otherf | 5 (1.3) | 3 (6.0) | 3 (23.1) | 0 (0) | 3 (7.0) |
| Irinotecan | 20 (5.2) | 3 (6.0) | 0 (0) | 3 (25.0) | 3 (7.0) |
| Temozolomidea | 20 (5.2) | 1 (2.0) | 1 (7.7) | 0 (0) | 11 (25.6) |
| Other monotherapy or combinations | 14 (3.6) | 8 (16.0) | 2 (15.4) | 4 (33.3) | 13 (30.2) |
Includes p.o. and i.v.
Example: overall, 76.5% of patients were treated with temozolomide during first-line therapy. Of those, 63.9% were treated with only bevacizumab during second-line therapy, and 18.2% had bevacizumab–irinotecan combination therapy.
Other agent(s) combined with temozolomide include carboplatin, chloroquine, cyclophosphamide, cisplatin, irinotecan, lomustine, methotrexate, thalidomide, and polifeprosan 20 with carmustine implant.
Other agent(s) combined with temozolomide + bevacizumab include carboplatin, carmustine, investigational treatment PLX3396, lomustine, irinotecan, and thalidomide.
As a proportion of first-line therapy.
Other agent(s) combined with bevacizumab include carboplatin, carmustine, cisplatin, erlotinib, etoposide, lomustine, investigational treatment PLX3396, and combination irinotecan + temozolomide.